Reduced levels of serotonin 2A receptors underlie resistance of EGR3-deficient mice to locomotor suppression by clozapine

Neuropsychopharmacology

Volumn 37, Issue 10, 2012, Pages 2285-2298

  Williams, Alison A ^a   Ingram, Wendy M ^b   Levine, Sarah ^c   Resnik, Jack ^d   Kamel, Christy M ^d   Lish, James R ^d   Elizalde, Diana I ^d   Janowski, Scott A ^c   Shoker, Joseph ^d   Kozlenkov, Alexey ^e   González Maeso, Javier ^e   Gallitano, Amelia L ^d  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

5HT2A receptor; clozapine; Egr3; immediate early gene; locomotor activity; schizophrenia antipsychotics

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; CHLORPROMAZINE; CLOZAPINE; DIPHENHYDRAMINE; EARLY GROWTH RESPONSE FACTOR 3; GLEMANSERIN; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; IFENPRODIL; KETANSERIN; MEDETOMIDINE; MEPYRAMINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMAVANSERIN; PROMETHAZINE; QUETIAPINE; RECEPTOR SUBTYPE; SCOPOLAMINE; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; TERAZOSIN; ZIPRASIDONE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BRAIN; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TARGETING; IMMEDIATE EARLY GENE; LOCOMOTION; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

ANIMALS; CLOZAPINE; DISEASE MODELS, ANIMAL; EARLY GROWTH RESPONSE PROTEIN 3; HUMANS; HYPNOTICS AND SEDATIVES; KETANSERIN; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT2A; SCHIZOPHRENIA; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN ANTAGONISTS;

EID: 84865250097     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.81     Document Type: Article

References (81)

1. Aitchison KJ, Jann MW, Zhao JH, Sakai T, Zaher H, Wolff K et al (2000). Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice. J Psychopharmacol 14: 353-359. (Pubitemid 32059779)
2. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ et al (2008). Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 40: 827-834. (Pubitemid 351913655)
3. Alves HN, da Silva AL, Olsson IA, Orden JM, Antunes LM (2010). Anesthesia with intraperitoneal propofol, medetomidine, and fentanyl in rats. J Am Assoc Lab Anim Sci 49: 454-459.
4. Bespalov A, Jongen-Relo AL, van Gaalen M, Harich S, Schoemaker H, Gross G (2007). Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. J Pharmacol Exp Ther 320: 944-950. (Pubitemid 46147979)
5. Buckton G, Zibrowski EM, Vanderwolf CH (2001). Effects of cyclazocine and scopolamine on swim-to-platform performance in rats. Brain Res 922: 229-233. (Pubitemid 34017484)
6. Casey DE (1997). The relationship of pharmacology to side effects. J Clin Psychiatry 58(Suppl 10): 55-62. (Pubitemid 27333182)
7. Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A (2005). Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res 1043: 32-41. (Pubitemid 40603369)
8. Crawley JN (1981). Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 15: 695-699. (Pubitemid 12195249)
9. Cutler NR (2001). Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. J Clin Psychiatry 62(Suppl 5): 10-13; discussion 23-14. (Pubitemid 32295158)
10. Darmani NA, Martin BR, Pandey U, Glennon RA (1990). Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol Biochem Behav 36: 901-906. (Pubitemid 20272314)
11. Dean B, Hayes W (1996). Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr Res 21: 133-139. (Pubitemid 26298405)
12. Dougherty JP, Aloyo VJ (2011). Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice. Psychopharmacology (Berl) 215: 581-593.
13. Erritzoe D, Rasmussen H, Kristiansen KT, Frokjaer VG, Haugbol S, Pinborg L et al (2008). Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology 33: 2435-2441.
14. Fox MA, Stein AR, French HT, Murphy DL (2010). Functional interactions between 5-HT2A and presynaptic 5-HT1A receptorbased responses in mice genetically deficient in the serotonin 5- HT transporter (SERT). Br J Pharmacol 159: 879-887.
15. Fukushiro DF, Alvarez Jdo N, Tatsu JA, de Castro JP, Chinen CC, Frussa-Filho R (2007). Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. Prog Neuropsychopharmacol Biol Psychiatry 31: 867-872. (Pubitemid 46661967)
16. Gainetdinov RR, Mohn AR, Caron MG (2001). Genetic animal models: focus on schizophrenia. Trends Neurosci 24: 527-533. (Pubitemid 32744707)
17. Gallitano-Mendel A, Izumi Y, Tokuda K, Zorumski CF, Howell MP, Muglia LJ et al (2007). The immediate early gene early growth response gene 3 mediates adaptation to stress and novelty. Neuroscience 148: 633-643. (Pubitemid 47418369)
18. Gallitano-Mendel A, Wozniak DF, Pehek EA, Milbrandt J (2008). Mice lacking the immediate early gene Egr3 respond to the antiaggressive effects of clozapine yet are relatively resistant to its sedating effects. Neuropsychopharmacology 33: 1266-1275. (Pubitemid 351521713)
19. Garbett K, Gal-Chis R, Gaszner G, Lewis DA, Mirnics K (2008). Transcriptome alterations in the prefrontal cortex of subjects with schizophrenia who committed suicide. Neuropsychopharmacol Hung 10: 9-14.
20. Geyer MA, Ellenbroek B (2003). Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27: 1071-1079. (Pubitemid 37464953)
21. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez- Gimenez JF et al (2008). Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452: 93-97. (Pubitemid 351355090)
22. Gonzalez-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M et al (2003). Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23: 8836-8843. (Pubitemid 37210895)
23. Guo AY, Sun J, Jia P, Zhao Z (2010). A novel microRNA and transcription factor mediated regulatory network in schizophrenia. BMC Syst Biol 4: 10.
24. Hippenmeyer S, Shneider NA, Birchmeier C, Burden SJ, Jessell TM, Arber S (2002). A role for neuregulin1 signaling in muscle spindle differentiation. Neuron 36: 1035-1049. (Pubitemid 36044506)
25. Hurlemann R, Matusch A, Kuhn KU, Berning J, Elmenhorst D, Winz O et al (2008). 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl) 195: 579-590. (Pubitemid 350160486)
26. Jacobson C, Duggan D, Fischbach G (2004). Neuregulin induces the expression of transcription factors and myosin heavy chains typical of muscle spindles in cultured human muscle. Proc Natl Acad Sci USA 101: 12218-12223. (Pubitemid 39145423)
27. Kamei J, Hirano S, Miyata S, Saitoh A, Onodera K (2005). Effects of first- and second-generation histamine-H1-receptor antagonists on the pentobarbital-induced loss of the righting reflex in streptozotocin-induced diabetic mice. J Pharmacol Sci 97: 266-272. (Pubitemid 40410267)
28. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796.
29. Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ et al (1996). Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277: 968-981.
30. Khan Z, Carey J, Park HJ, Lehar M, Lasker D, Jinnah HA (2004). Abnormal motor behavior and vestibular dysfunction in the stargazer mouse mutant. Neuroscience 127: 785-796. (Pubitemid 38993179)
31. Kim SH, Song JY, Joo EJ, Lee KY, Ahn YM, Kim YS (2010). EGR3 as a potential susceptibility gene for schizophrenia in Korea. Am J Med Genet B 153B: 1355-1360.
32. Kinkead B, Dobner PR, Egnatashvili V, Murray T, Deitemeyer N, Nemeroff CB (2005). Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine. J Pharmacol Exp Ther 315: 256-264. (Pubitemid 41380519)
33. Kyncl JJ (1986). Pharmacology of terazosin. Am J Med 80: 12-19. (Pubitemid 16047544)
34. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A et al (2007). Genome-wide atlas of gene expression in the adult mouse brain. Nature 445: 168-176. (Pubitemid 46095716)
35. Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini- Dodel D, Burke S, Akil H et al (2004). Serotonin 5-HT1A, 5- HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 55: 225-233. (Pubitemid 38117158)
36. Lynch III JJ, Castagne V, Moser PC, Mittelstadt SW (2011). Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies. J Pharmacol Toxicol Methods 64: 74-80.
37. MacDonald E, Scheinin M, Scheinin H, Virtanen R (1991). Comparison of the behavioral and neurochemical effects of the two optical enantiomers of medetomidine, a selective alpha-2- adrenoceptor agonist. J Pharmacol Exp Ther 259: 848-854.
38. Matsumoto I, Inoue Y, Iwazaki T, Pavey G, Dean B (2005). 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci Lett 379: 164-168. (Pubitemid 40544527)
39. McNamara RK, Logue A, Stanford K, Xu M, Zhang J, Richtand NM (2006). Doseresponse analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine. Synapse 60: 399-405. (Pubitemid 44215843)
40. McOmish CE, Lira A, Hanks JB, Gingrich JA (2010). Clozapineinduced locomotor suppression is mediated by the cortical 5-HT2A receptor in mice. Neuropsychopharmacology 35: S228.
41. Meltzer HY, Huang M (2008). In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172: 177-197.
42. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 1159-1172. (Pubitemid 37464960)
43. Meltzer HY, Matsubara S, Lee JC (1989). The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25: 390-392. (Pubitemid 20260244)
44. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D et al (2010). Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology 35: 881-892.
45. Mexal S, Frank M, Berger R, Adams CE, Ross RG, Freedman R et al (2005). Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. Brain Res Mol Brain Res 139: 317-332. (Pubitemid 41317945)
46. Mittelstadt PR, Ashwell JD (1998). Cyclosporin A-sensitive transcription factor Egr-3 regulates Fas ligand expression. Mol Cell Biol 18: 3744-3751. (Pubitemid 28287896)
47. Moore NA, Tye NC, Axton MS, Risius FC (1992). The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 262: 545-551.
48. Ngan ET, Yatham LN, Ruth TJ, Liddle PF (2000). Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(18)F]setoperone. Am J Psychiatry 157: 1016-1018. (Pubitemid 30412359)
49. O'Dell LE, Kreifeldt MJ, George FR, Ritz MC (2000). The role of serotonin(2) receptors in mediating cocaine-induced convulsions. Pharmacol Biochem Behav 65: 677-681. (Pubitemid 30182512)
50. Oduola OO, Happi TC, Gbotosho GO, Ogundahunsi OA, Falade CO, Akinboye DO et al (2004). Plasmodium berghei: efficacy and safety of combinations of chloroquine and promethazine in chloroquine resistant infections in gravid mice. Afr J Med Med Sci 33: 77-81.
51. Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33: 523-533.
52. Owen MJ, Craddock N, O'Donovan MC (2010). Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia. Arch Gen Psychiatry 67: 667-673.
53. Parsons ME, Ganellin CR (2006). Histamine and its receptors. Br J Pharmacol 147(Suppl 1): S127-S135. (Pubitemid 43077270)
54. Philibin SD, Prus AJ, Pehrson AL, Porter JH (2005). Serotonin receptor mechanisms mediate the discriminative stimulus properties of the atypical antipsychotic clozapine in C57BL/6 mice. Psychopharmacology (Berl) 180: 49-56. (Pubitemid 40897070)
55. Pierre JM (2005). Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 28: 191-208. (Pubitemid 40364887)
56. Rasmussen H, Erritzoe D, Andersen R, Ebdrup BH, Aggernaes B, Oranje B et al (2010). Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry 67: 9-16.
57. Rasmussen T, Fink-Jensen A (2000). Intravenous scopolamine is potently self-administered in drug-naive mice. Neuropsychopharmacology 22: 97-99.
58. Redrobe JP, Bourin M (1997). Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 325: 129-135. (Pubitemid 27199561)
59. Rosen GD, Capra JA, Connolly MT, Cruz B, Lu L, Airey DC et al. (2000). The Mouse Brain Library. Int Mouse Genome Conf 14: 166.
60. Roth BL. Psychoactive Drug Screening Program, Contract No. HHSN-271-2008-00025-C (NIMH PDSP) 2008. http://pdsp.med.unc.edu/.
61. Roth BL, Sheffler DJ, Kroeze WK (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3: 353-359. (Pubitemid 38499762)
62. Serretti A, Drago A, De Ronchi D (2007). HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem 14: 2053-2069. (Pubitemid 47578163)
63. Shishido S, Oishi R, Saeki K (1991). In vivo effects of some histamine H1-receptor antagonists on monoamine metabolism in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol 343: 185-189.
64. Simon VM, Parra A, Minarro J, Arenas MC, Vinader-Caerols C, Aguilar MA (2000). Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice. Eur Neuropsychopharmacol 10: 159-164. (Pubitemid 30227615)
65. Stahl S (2008). Stahl's Essential Psychopharmacology; 3rd edn. Cambridge University Press: New York, 1117pp.
66. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S et al (2002). Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71: 877-892. (Pubitemid 135750519)
67. Teegarden BR, Al Shamma H, Xiong Y (2008). 5-HT(2A) inverseagonists for the treatment of insomnia. Curr Top Med Chem 8: 969-976.
68. Tourtellotte WG, Milbrandt J (1998). Sensory ataxia and muscle spindle agenesis in mice lacking the transcription factor Egr3. Nat Genet 20: 87-91. (Pubitemid 28410352)
69. Vanderwolf CH (1991). Anti-muscarinic drug effects in a swim-toplatform test: dose-response relations. Behav Brain Res 44: 217-219.
70. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J et al (2006). Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1- methylpiperidin-4-yl)-N0-(4-(2- methylpropylo xy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2 : 1) (ACP-103), a novel 5-hydroxytryptamine (2A) receptor inverse agonist. J Pharmacol Exp Ther 317: 910-918.
71. Votava M, Hess L, Krsiak M (2008). Selective antiaggressive effect of an alpha-2 adrenoceptor agonist naphthylmedetomidine in mice. Aggress Behav 34: 394-403.
72. Weber ET, Andrade R (2010). Htr2a gene and 5-HT(2A) receptor expression in the cerebral cortex studied using genetically modified mice. Front Neurosci 4.
73. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D et al (2008). DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36: D901-D906. (Pubitemid 351149842)
74. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P et al (2006). DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34: D668-D672.
75. Yadav PN, Abbas AI, Farrell MS, Setola V, Sciaky N, Huang XP et al (2011). The presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacology 36: 638-651.
76. Yamada K, Gerber DJ, Iwayama Y, Ohnishi T, Ohba H, Toyota T et al (2007). Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia. Proc Natl Acad Sci USA 104: 2815-2820. (Pubitemid 46327962)
77. Yamagata K, Kaufmann WE, Lanahan A, Papapavlou M, Barnes CA, Andreasson KI et al (1994). Egr3/Pilot, a zinc finger transcription factor, is rapidly regulated by activity in brain neurons and colocalizes with Egr1/zif268. Learn Mem 1: 140-152. (Pubitemid 2143751)
78. Yan B, He J, Xu H, Zhang Y, Bi X, Thakur S et al (2007). Quetiapine attenuates the depressive and anxiolytic-like behavioural changes induced by global cerebral ischemia in mice. Behav Brain Res 182: 36-41. (Pubitemid 47042189)
79. Zarnowski T, Kleinrok Z, TurskiWA, Czuczwar SJ (1994). The NMDA antagonist procyclidine, but not ifenprodil, enhances the protective efficacy of common antiepileptics against maximal electroshockinduced seizures in mice. J Neural Transm Gen Sect 97: 1-12.
80. Zhang R, Lu S, Meng L, Min Z, Tian J, Valenzuela RK (2012). Genetic evidence for the association between the early growth response 3 (EGR3) gene and schizophrenia. PLoS One 7: e30237.
81. Zhu CZ, Wilson SG, Mikusa JP, Wismer CT, Gauvin DM, Lynch III JJ et al (2004). Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol 506: 107-118. (Pubitemid 39592907)